Wells Fargo & Company Cuts Medline (NASDAQ:MDLN) Price Target to $34.00

Medline (NASDAQ:MDLN) had its price objective trimmed by Wells Fargo & Company from $45.00 to $34.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

Other equities research analysts have also recently issued research reports about the company. Stifel Nicolaus cut their price target on Medline from $50.00 to $45.00 and set a “buy” rating for the company in a report on Thursday, August 6th. BMO Capital Markets reissued an “outperform” rating and set a $47.00 price objective on shares of Medline in a research note on Thursday, August 6th. Barclays dropped their target price on Medline from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Monday, June 1st. Citigroup raised Medline to a “strong-buy” rating in a research note on Wednesday, August 5th. Finally, TD Cowen reduced their price target on Medline from $53.00 to $45.00 and set a “buy” rating on the stock in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $47.42.

Medline Stock Up 0.2%

Shares of NASDAQ MDLN opened at $35.58 on Tuesday. The stock has a market cap of $46.74 billion and a PE ratio of 111.19. The company has a current ratio of 4.33, a quick ratio of 2.61 and a debt-to-equity ratio of 0.66. Medline has a 12-month low of $32.81 and a 12-month high of $50.88. The company has a 50-day moving average of $38.26 and a 200 day moving average of $41.43.

Medline (NASDAQ:MDLN) last released its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.18. The business had revenue of $7.68 billion during the quarter. As a group, sell-side analysts predict that Medline will post 1.49 EPS for the current fiscal year.

Insider Activity

In other Medline news, insider Jessi L. Corcoran bought 5,000 shares of the business’s stock in a transaction on Friday, June 5th. The stock was bought at an average price of $34.15 per share, with a total value of $170,750.00. Following the completion of the purchase, the insider directly owned 5,000 shares in the company, valued at $170,750. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Douglas P. Golwas sold 100,000 shares of Medline stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $36.77, for a total value of $3,677,000.00. Following the completion of the sale, the insider owned 23,899 shares in the company, valued at $878,766.23. This represents a 80.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 2,938,896 shares of company stock valued at $104,656,454. 0.81% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Medline

A number of hedge funds have recently modified their holdings of the business. Sound Income Strategies LLC purchased a new stake in Medline in the 4th quarter valued at about $25,000. GAMMA Investing LLC boosted its stake in Medline by 68.3% during the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock worth $25,000 after buying an additional 254 shares during the period. Entrust Financial LLC purchased a new position in Medline during the fourth quarter worth about $26,000. NBC Securities Inc. acquired a new stake in shares of Medline during the fourth quarter valued at about $28,000. Finally, Whipplewood Advisors LLC acquired a new stake in shares of Medline during the first quarter valued at about $30,000.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline’s second-quarter results were a key support for the stock: earnings of $0.50 per share exceeded the $0.32 consensus estimate, while revenue reached approximately $7.7 billion. The earnings call provided investors with additional management commentary on the company’s outlook. Medline Q2 2026 earnings call transcript
• Positive Sentiment: JPMorgan lowered its price target to $46 but retained an Overweight rating, while TD Cowen and Tigress Financial maintained positive ratings with targets of $45 and $55, respectively. These targets imply meaningful upside and suggest some analysts view the recent weakness as excessive.
• Neutral Sentiment: Despite multiple target reductions, analyst sentiment remains broadly favorable. Medline has a consensus rating of “Moderate Buy,” although the average target has fallen to about $47.69, indicating that expectations are being recalibrated.
• Negative Sentiment: Medline convenience kits are affected by recalled Becton Dickinson applicators linked to sterility and contamination risks. The FDA alert and Medline’s corrective actions could create operational, regulatory and reputational concerns, although the report does not indicate the full financial impact. FDA alert on Medline convenience kits
• Negative Sentiment: Kaplan Fox and Kessler Topaz Meltzer & Check announced investigations into potential securities-law violations. The announcements do not establish wrongdoing, but they add legal uncertainty and may weigh on investor confidence. Kessler Topaz Medline investigation
• Negative Sentiment: Wells Fargo cut its price target to $34 and assigned an Equal Weight rating, signaling limited near-term upside. Major shareholder GIC also sold additional Medline shares, including 590,284 shares in the latest disclosed transaction, reducing its position by 2.36%.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.